Skip to main content
Erschienen in: Der Internist 2/2018

27.11.2017 | Paraneoplastische Syndrome | Schwerpunkt: Paraneoplastische Syndrome

Metabolische Entgleisungen als paraneoplastische Syndrome

verfasst von: Dr. S. Krug, Prof. Dr. P. Michl

Erschienen in: Die Innere Medizin | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Paraneoplastische Syndrome sind charakterisiert durch die tumorinduzierte Freisetzung von Peptidhormonen und/oder die Induktion von Immunphänomenen, die von der Tumormasse völlig unabhängige klinische und laborchemische Veränderungen hervorrufen. Neben neurologischen, endokrinen und rheumatologischen Erscheinungsformen spielen im klinischen Alltag metabolische Veränderungen eine besondere Rolle, die aufgrund ihrer oftmals akuten Symptomatik medizinische Notfälle darstellen und einer zügigen Diagnosestellung und prompten Therapieeinleitung bedürfen. Metabolische Veränderungen im Rahmen von malignen Erkrankungen sollen in einem interdisziplinären Team behandelt werden, oftmals ist hierzu auch ein intensivmedizinisches Monitoring nötig. Im Folgenden werden Diagnostik und Therapiemöglichkeiten paraneoplastisch bedingter metabolischer Entgleisungen dargestellt. Beispiele sind Hyperkalzämie, Hypokalzämie, Hyperglykämie und Hypoglykämie sowie als Sonderform tumorassoziierte metabolische Entgleisungen durch das Tumorlysesyndrom.
Literatur
1.
Zurück zum Zitat Agnani S, Gupta R, Atray NK et al (2006) Marked hyperuricemia with acute renal failure: need to consider occult malignancy and spontaneous tumour lysis syndrome. Int J Clin Pract 60:364–366CrossRefPubMed Agnani S, Gupta R, Atray NK et al (2006) Marked hyperuricemia with acute renal failure: need to consider occult malignancy and spontaneous tumour lysis syndrome. Int J Clin Pract 60:364–366CrossRefPubMed
2.
Zurück zum Zitat Albright F, Burnett CH, Cope O, Parson W (1941) Acute atrophy of bone (osteoporosis) simulating hyperthyreodism12. J Clin Endocrinol 1:711–716CrossRef Albright F, Burnett CH, Cope O, Parson W (1941) Acute atrophy of bone (osteoporosis) simulating hyperthyreodism12. J Clin Endocrinol 1:711–716CrossRef
3.
Zurück zum Zitat Austin LA, Heath H (1981) Calcitonin: physiology and pathophysiology. N Engl J Med 304:269–278CrossRefPubMed Austin LA, Heath H (1981) Calcitonin: physiology and pathophysiology. N Engl J Med 304:269–278CrossRefPubMed
4.
Zurück zum Zitat Açıkgöz Y, Sendur MA, Ozdemir NY et al (2014) Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia. J Craniomaxillofac Surg 42:277–278CrossRefPubMed Açıkgöz Y, Sendur MA, Ozdemir NY et al (2014) Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia. J Craniomaxillofac Surg 42:277–278CrossRefPubMed
5.
Zurück zum Zitat Baijens LW, Manni JJ (2006) Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature. Eur Arch Otorhinolaryngol 263:32–36CrossRefPubMed Baijens LW, Manni JJ (2006) Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature. Eur Arch Otorhinolaryngol 263:32–36CrossRefPubMed
6.
Zurück zum Zitat Bech A, de Boer H (2012) Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med 156:906–907CrossRefPubMed Bech A, de Boer H (2012) Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med 156:906–907CrossRefPubMed
7.
Zurück zum Zitat Becker MA, Schumacher HR, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461CrossRefPubMed Becker MA, Schumacher HR, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461CrossRefPubMed
8.
Zurück zum Zitat Becker MA, Schumacher HR, MacDonald PA et al (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36:1273–1282CrossRefPubMed Becker MA, Schumacher HR, MacDonald PA et al (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36:1273–1282CrossRefPubMed
9.
Zurück zum Zitat Ben Q, Xu M, Ning X et al (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47:1928–1937CrossRefPubMed Ben Q, Xu M, Ning X et al (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47:1928–1937CrossRefPubMed
11.
Zurück zum Zitat Blomqvist CP (1986) A hospital survey of hypocalcemia in patients with malignant disease. Acta Med Scand 220:167–173CrossRefPubMed Blomqvist CP (1986) A hospital survey of hypocalcemia in patients with malignant disease. Acta Med Scand 220:167–173CrossRefPubMed
12.
Zurück zum Zitat Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11CrossRefPubMed Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11CrossRefPubMed
13.
Zurück zum Zitat Cairo MS, Coiffier B, Reiter A et al (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578–586CrossRefPubMed Cairo MS, Coiffier B, Reiter A et al (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578–586CrossRefPubMed
14.
Zurück zum Zitat Cairo MS, Thompson S, Tangirala K et al (2017) A clinical and economic comparison of Rasburicase and Allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. Clin Lymphoma Myeloma Leuk 17:173–178CrossRefPubMed Cairo MS, Thompson S, Tangirala K et al (2017) A clinical and economic comparison of Rasburicase and Allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. Clin Lymphoma Myeloma Leuk 17:173–178CrossRefPubMed
15.
Zurück zum Zitat Catania VE, Vecchio M, Malaguarnera M et al (2017) Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature. J Med Case Rep 11:79CrossRefPubMedPubMedCentral Catania VE, Vecchio M, Malaguarnera M et al (2017) Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature. J Med Case Rep 11:79CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Chari ST, Leibson CL, Rabe KG et al (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129:504–511CrossRefPubMedPubMedCentral Chari ST, Leibson CL, Rabe KG et al (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129:504–511CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Chen K, Qian W, Jiang Z et al (2017) Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer 16:131CrossRefPubMedPubMedCentral Chen K, Qian W, Jiang Z et al (2017) Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer 16:131CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cicci JD, Buie L, Bates J et al (2014) Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk 14:e207–e211CrossRefPubMed Cicci JD, Buie L, Bates J et al (2014) Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk 14:e207–e211CrossRefPubMed
19.
Zurück zum Zitat Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12:549–583CrossRefPubMed Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12:549–583CrossRefPubMed
20.
Zurück zum Zitat Coiffier B, Altman A, Pui CH et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778CrossRefPubMed Coiffier B, Altman A, Pui CH et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778CrossRefPubMed
21.
Zurück zum Zitat Coners K, Woods SE, Webb M (2011) Dual paraneoplastic syndromes in a patient with small cell lung cancer: a case report. J Med Case Rep 5:318CrossRefPubMedPubMedCentral Coners K, Woods SE, Webb M (2011) Dual paraneoplastic syndromes in a patient with small cell lung cancer: a case report. J Med Case Rep 5:318CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Cortes J, Moore JO, Maziarz RT et al (2010) Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone – results of a multicenter phase III study. J Clin Oncol 28:4207–4213CrossRefPubMedPubMedCentral Cortes J, Moore JO, Maziarz RT et al (2010) Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone – results of a multicenter phase III study. J Clin Oncol 28:4207–4213CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Cvijovic G, Micic D, Kendereski A et al (2013) Ectopic calcitonin secretion in a woman with large cell neuroendocrine lung carcinoma. Hormones (Athens) 12:584–590CrossRef Cvijovic G, Micic D, Kendereski A et al (2013) Ectopic calcitonin secretion in a woman with large cell neuroendocrine lung carcinoma. Hormones (Athens) 12:584–590CrossRef
24.
Zurück zum Zitat Darmon M, Guichard I, Vincent F (2011) Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. J Clin Oncol 29:e67–e68 (author reply e69)CrossRefPubMed Darmon M, Guichard I, Vincent F (2011) Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. J Clin Oncol 29:e67–e68 (author reply e69)CrossRefPubMed
25.
Zurück zum Zitat Darmon M, Vincent F, Camous L et al (2013) Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol 162:489–497CrossRefPubMed Darmon M, Vincent F, Camous L et al (2013) Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol 162:489–497CrossRefPubMed
26.
Zurück zum Zitat Davidson MB, Thakkar S, Hix JK et al (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546–554CrossRefPubMed Davidson MB, Thakkar S, Hix JK et al (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546–554CrossRefPubMed
28.
Zurück zum Zitat Diel IJ, Body JJ, Stopeck AT et al (2015) The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer 51:1467–1475CrossRefPubMed Diel IJ, Body JJ, Stopeck AT et al (2015) The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer 51:1467–1475CrossRefPubMed
30.
Zurück zum Zitat Van den Eynden GG, Neyret A, Fumey G et al (2007) PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor. Bone 40:1166–1171CrossRefPubMed Van den Eynden GG, Neyret A, Fumey G et al (2007) PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor. Bone 40:1166–1171CrossRefPubMed
32.
Zurück zum Zitat Han G, Zhang Z, Shen X et al (2017) Doege-potter syndrome: a review of the literature including a new case report. Medicine (Baltimore) 96:e7417CrossRef Han G, Zhang Z, Shen X et al (2017) Doege-potter syndrome: a review of the literature including a new case report. Medicine (Baltimore) 96:e7417CrossRef
35.
Zurück zum Zitat Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercalcaemia. Q J Med 50:473–481PubMed Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercalcaemia. Q J Med 50:473–481PubMed
37.
Zurück zum Zitat Hu MI, Glezerman IG, Leboulleux S et al (2014) Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99:3144–3152CrossRefPubMedPubMedCentral Hu MI, Glezerman IG, Leboulleux S et al (2014) Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99:3144–3152CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Hutchesson AC, Bundred NJ, Ratcliffe WA (1995) Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 71:28–31CrossRefPubMedPubMedCentral Hutchesson AC, Bundred NJ, Ratcliffe WA (1995) Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 71:28–31CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Huxley R, Ansary-Moghaddam A, Berrington de González A et al (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083CrossRefPubMedPubMedCentral Huxley R, Ansary-Moghaddam A, Berrington de González A et al (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Iglesias P, Díez JJ (2014) Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol 170:R147–R157CrossRefPubMed Iglesias P, Díez JJ (2014) Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol 170:R147–R157CrossRefPubMed
42.
Zurück zum Zitat Kaltsas G, Androulakis II, de Herder WW et al (2010) Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer 17:R173–R193CrossRefPubMed Kaltsas G, Androulakis II, de Herder WW et al (2010) Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer 17:R173–R193CrossRefPubMed
44.
Zurück zum Zitat Kleeff J, Costello E, Jackson R et al (2016) The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer 115:887–894CrossRefPubMedPubMedCentral Kleeff J, Costello E, Jackson R et al (2016) The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer 115:887–894CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Korevaar TI, Ragazzoni F, Weaver A et al (2014) IGF2-induced hypoglycemia unresponsive to everolimus. QJM 107:297–300CrossRefPubMed Korevaar TI, Ragazzoni F, Weaver A et al (2014) IGF2-induced hypoglycemia unresponsive to everolimus. QJM 107:297–300CrossRefPubMed
46.
Zurück zum Zitat Ladenson JH, Lewis JW, McDonald JM et al (1979) Relationship of free and total calcium in hypercalcemic conditions. J Clin Endocrinol Metab 48:393–397CrossRefPubMed Ladenson JH, Lewis JW, McDonald JM et al (1979) Relationship of free and total calcium in hypercalcemic conditions. J Clin Endocrinol Metab 48:393–397CrossRefPubMed
48.
Zurück zum Zitat LeGrand SB, Leskuski D, Zama I (2008) Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 149:259–263CrossRefPubMed LeGrand SB, Leskuski D, Zama I (2008) Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 149:259–263CrossRefPubMed
49.
Zurück zum Zitat Ling PJ, A’Hern RP, Hardy JR (1995) Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 72:206–209CrossRefPubMedPubMedCentral Ling PJ, A’Hern RP, Hardy JR (1995) Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 72:206–209CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Lopez-Olivo MA, Pratt G, Palla SL et al (2013) Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis 62:481–492CrossRefPubMed Lopez-Olivo MA, Pratt G, Palla SL et al (2013) Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis 62:481–492CrossRefPubMed
51.
Zurück zum Zitat Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558–567CrossRefPubMed Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558–567CrossRefPubMed
52.
Zurück zum Zitat Mayer S, Cypess AM, Kocher ON et al (2005) Uncommon presentations of some common malignancies: case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer. J Clin Oncol 23:1312–1314CrossRefPubMed Mayer S, Cypess AM, Kocher ON et al (2005) Uncommon presentations of some common malignancies: case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer. J Clin Oncol 23:1312–1314CrossRefPubMed
54.
Zurück zum Zitat Montesinos P, Lorenzo I, Martín G et al (2008) Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 93:67–74CrossRefPubMed Montesinos P, Lorenzo I, Martín G et al (2008) Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 93:67–74CrossRefPubMed
55.
Zurück zum Zitat Ngo N, Edriss H, Figueroa JA et al (2014) Squamous cell carcinoma of the sigmoid colon presenting with severe hypercalcemia. Clin Colorectal Cancer 13:251–254CrossRefPubMed Ngo N, Edriss H, Figueroa JA et al (2014) Squamous cell carcinoma of the sigmoid colon presenting with severe hypercalcemia. Clin Colorectal Cancer 13:251–254CrossRefPubMed
56.
Zurück zum Zitat Oberg K, Krenning E, Sundin A et al (2016) A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 5:174–187CrossRefPubMedPubMedCentral Oberg K, Krenning E, Sundin A et al (2016) A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 5:174–187CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Otake S, Kikkawa T, Takizawa M et al (2015) Hypoglycemia observed on continuous glucose monitoring associated with IGF-2-producing solitary fibrous tumor. J Clin Endocrinol Metab 100:2519–2524CrossRefPubMed Otake S, Kikkawa T, Takizawa M et al (2015) Hypoglycemia observed on continuous glucose monitoring associated with IGF-2-producing solitary fibrous tumor. J Clin Endocrinol Metab 100:2519–2524CrossRefPubMed
58.
Zurück zum Zitat Pannala R, Leirness JB, Bamlet WR et al (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134:981–987CrossRefPubMedPubMedCentral Pannala R, Leirness JB, Bamlet WR et al (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134:981–987CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Pecherstorfer M, Steinhauer EU, Rizzoli R et al (2003) Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 11:539–547CrossRefPubMed Pecherstorfer M, Steinhauer EU, Rizzoli R et al (2003) Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 11:539–547CrossRefPubMed
60.
Zurück zum Zitat Pelaez-Luna M, Takahashi N, Fletcher JG et al (2007) Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 102:2157–2163CrossRefPubMed Pelaez-Luna M, Takahashi N, Fletcher JG et al (2007) Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 102:2157–2163CrossRefPubMed
61.
Zurück zum Zitat Riancho JA, Arjona R, Valle R et al (1989) The clinical spectrum of hypocalcaemia associated with bone metastases. J Intern Med 226:449–452CrossRefPubMed Riancho JA, Arjona R, Valle R et al (1989) The clinical spectrum of hypocalcaemia associated with bone metastases. J Intern Med 226:449–452CrossRefPubMed
62.
Zurück zum Zitat Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRefPubMed Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRefPubMed
63.
Zurück zum Zitat Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347CrossRefPubMed Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347CrossRefPubMed
64.
Zurück zum Zitat Sah RP, Nagpal SJ, Mukhopadhyay D et al (2013) New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10:423–433CrossRefPubMedPubMedCentral Sah RP, Nagpal SJ, Mukhopadhyay D et al (2013) New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10:423–433CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Shen H, Zhan M, Wang W et al (2016) Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis. Onco Targets Ther 9:1679–1688PubMedPubMedCentral Shen H, Zhan M, Wang W et al (2016) Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis. Onco Targets Ther 9:1679–1688PubMedPubMedCentral
66.
Zurück zum Zitat Shivnani SB, Shelton JM, Richardson JA et al (2009) Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone – related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma. Endocr Pract 15:234–239CrossRefPubMedPubMedCentral Shivnani SB, Shelton JM, Richardson JA et al (2009) Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone – related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma. Endocr Pract 15:234–239CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Soyfoo MS, Brenner K, Paesmans M et al (2013) Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence. Support Care Cancer 21:1415–1419CrossRefPubMed Soyfoo MS, Brenner K, Paesmans M et al (2013) Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence. Support Care Cancer 21:1415–1419CrossRefPubMed
68.
Zurück zum Zitat Spina M, Nagy Z, Ribera JM et al (2015) FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol 26:2155–2161CrossRefPubMed Spina M, Nagy Z, Ribera JM et al (2015) FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol 26:2155–2161CrossRefPubMed
69.
Zurück zum Zitat Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373–379CrossRefPubMed Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373–379CrossRefPubMed
70.
Zurück zum Zitat Tamura K, Kawai Y, Kiguchi T et al (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21:996–1003CrossRefPubMed Tamura K, Kawai Y, Kiguchi T et al (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21:996–1003CrossRefPubMed
71.
Zurück zum Zitat Teale JD, Wark G (2004) The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clin Endocrinol (Oxf) 60:457–460CrossRef Teale JD, Wark G (2004) The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clin Endocrinol (Oxf) 60:457–460CrossRef
72.
Zurück zum Zitat Tosi P, Barosi G, Lazzaro C et al (2008) Consensus conference on the management of tumor lysis syndrome. Haematologica 93:1877–1885CrossRefPubMed Tosi P, Barosi G, Lazzaro C et al (2008) Consensus conference on the management of tumor lysis syndrome. Haematologica 93:1877–1885CrossRefPubMed
73.
Zurück zum Zitat Trimarchi H, Lombi F, Forrester M et al (2006) Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. Nat Clin Pract Nephrol 2:459–463 (quiz 464)CrossRefPubMed Trimarchi H, Lombi F, Forrester M et al (2006) Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. Nat Clin Pract Nephrol 2:459–463 (quiz 464)CrossRefPubMed
74.
Zurück zum Zitat Tsoli M, Robertson G (2013) Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab 24:174–183CrossRefPubMed Tsoli M, Robertson G (2013) Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab 24:174–183CrossRefPubMed
75.
Zurück zum Zitat VanHouten JN, Yu N, Rimm D et al (2006) Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 91:580–583CrossRefPubMed VanHouten JN, Yu N, Rimm D et al (2006) Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 91:580–583CrossRefPubMed
76.
Zurück zum Zitat Vassilopoulou-Sellin R, Newman BM, Taylor SH et al (1993) Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71:1309–1312CrossRefPubMed Vassilopoulou-Sellin R, Newman BM, Taylor SH et al (1993) Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71:1309–1312CrossRefPubMed
77.
Zurück zum Zitat Wada S, Yasuda S (2001) Appropriate clinical usage of calcitonin escape phenomenon and intermittent v.s. daily administration of calcitonin. Clin Calcium 11:1169–1175PubMed Wada S, Yasuda S (2001) Appropriate clinical usage of calcitonin escape phenomenon and intermittent v.s. daily administration of calcitonin. Clin Calcium 11:1169–1175PubMed
79.
Zurück zum Zitat Wössmann W, Schrappe M, Meyer U et al (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82:160–165PubMed Wössmann W, Schrappe M, Meyer U et al (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82:160–165PubMed
80.
81.
Zurück zum Zitat Yamada Y, Kohashi K, Fushimi F et al (2014) Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors. Cancer 120:864–876CrossRefPubMed Yamada Y, Kohashi K, Fushimi F et al (2014) Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors. Cancer 120:864–876CrossRefPubMed
82.
Zurück zum Zitat Zhou PT, Li B, Liu FR et al (2017) Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget 8:25242–25250PubMedPubMedCentral Zhou PT, Li B, Liu FR et al (2017) Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget 8:25242–25250PubMedPubMedCentral
83.
Zurück zum Zitat Zudaire E, Cuttitta F, Martínez A (2003) Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regul Pept 112:121–130CrossRefPubMed Zudaire E, Cuttitta F, Martínez A (2003) Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regul Pept 112:121–130CrossRefPubMed
Metadaten
Titel
Metabolische Entgleisungen als paraneoplastische Syndrome
verfasst von
Dr. S. Krug
Prof. Dr. P. Michl
Publikationsdatum
27.11.2017
Verlag
Springer Medizin
Erschienen in
Die Innere Medizin / Ausgabe 2/2018
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-017-0357-2

Weitere Artikel der Ausgabe 2/2018

Der Internist 2/2018 Zur Ausgabe

Einführung zum Thema

Paraneoplastische Syndrome

Mitteilungen der DGIM

Mitteilungen der DGIM

Kongresse des BDI

Kongresse des BDI

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.